Recital 1, Commission Delegated Regulation (EU) No 357/2014 of 3 February 2014 supplementing Direct…

In forcesince 3 Feb 2014

Authorisation decisions for medicinal products should be made on the basis of the objective criteria of quality, safety and efficacy of the medicinal product concerned, to ensure that only high quality medicinal products are placed on the market and administered to patients. As a consequence, new medicinal products have to undergo extensive studies, including clinical efficacy trials, before they are authorised.